|
BioScreening - organic compounds for screening
HIV ResearchAIDS Drugs – HIV - In the early 1980s, the human immunodeficiency virus (HIV) was identiÂfied as the etiologic agent of acquired immune deficiency syndrome (AIDS). More than 3 million people worldwide died from HIV/AIDS in 2003, according to a July 2004 United Nations report. During the same period, about 5 million people contracted the human immunodeficiency virus, bringing the [...]
Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds: NIAID contracts additional $700,000 to screen 300,000 more compounds for HIV inhibition - Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds: NIAID contracts additional $700,000 to screen 300,000 more compounds for HIV inhibition
PRNewswire - October 28, 2009
CARY, N.C. and BIRMINGHAM, Ala., Oct. 28 /PRNewswire-USNewswire/ — Trana Discovery, Inc., an infectious disease drug discovery technology company, and Southern Research Institute, a not-for-profit contract research organization conducting [...]
Researchers find candidates for new HIV drugs - While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.
HIV drug discovery efforts have met with little success in finding compounds that interact with an important HIV virulence factor, called Nef, [...]
Progress in Finding a New Class of HIV Drugs - Scientists have discovered a method for screening an entirely new class of drugs, targeted against the HIV protein Nef, according to an article published online October 6 in ACS Chemical Biology and reported by ScienceDaily.
HIV’s Nef protein has an important indirect influence on how well HIV functions in the body. The presence of Nef inhibits [...]
AIDS Study Flushes Out Hidden Virus, Pointing to Possible Cure - Oct. 2 (Bloomberg) — Scientists, moving closer to a cure for AIDS, identified a way to find medicines that would help rid patients of the hardest-to-treat pockets of HIV.
Current anti-HIV drugs reduce the virus to undetectable levels without eradicating it. The virus survives by lying dormant in immune-system cells, where the medicines don’t reach them. [...]
Virtual Screening Gives Drug Design a Boost - San Diego, CA (OBBeC) – Researchers at the University of California, San Diego, developed a unique computational approach to identify key compounds that could lead to new drugs to combat African sleeping sickness — a disease spread by the biting tsetse fly and caused by the parasite Trypanosoma brucei.
Around 150,000 people per year get African [...]
Seegene/Lab901 brings a New Detection Platform for Multiple Pathogens to European Hospitals - Rockville, MD, and Edinburgh, Scotland, June 17, 2008:Â Seegene and Lab901 today announced the availability of a novel automated multi-pathogen walk-away detection platform for European hospitals. Based on the Seeplex(R) multiplexing PCR system and ScreenTape(R)Â gel electrophoresis detection system, this new Seeplex/ScreenTape detection platform will be introduced to clinical and [...]
Validated biomarkers will drive personalized medicine - Biomarkers will be accepted as predicted tools, but their clinical usefulness needs to be understood
first, according to personalized medicine expert.
Coordinating personalized medicine on an international level, Dr Edward Abrahams, Executive
Director of the Personalized Medicine Coalition believes that biomarkers will eventually impact all
disease areas.
“When they were validated, and when it can be understood how clinically useful [...]
Health Care’s Silent Spring - As the Intergovernmental Working Group (IGWG) of the WHO prepares to meet and discuss how to best facilitate the expropriation of intellectual property rights (in this case the IPR of pharmaceutical patents) it’s important to consider the unintended consequences — the death of medical innovation.
The global purloiners of patents — led by Jamie Love — [...]
ViroStatics Establishes Scientific Advisory Board for HIV Development Program - SASSARI, Italy & PRINCETON, N.J. - (Business Wire) ViroStatics, srl, a privately-held pharmaceutical company focused on the discovery and development of combination therapeutics in HIV/AIDS, virology, and other chronic diseases, today announced the formation of a Scientific Advisory Board (SAB). Chaired by Daniel Kuritzkes, MD, Director of AIDS Research, [...]
SRI helps develop screening program for AIDS drugs - Research conducted at Birmingham’s Southern Research Institute helped develop a system to identify drugs with the ability to fight the virus that causes AIDS.
Trana Discovery, a North Carolina-based drug discovery technology company, worked with Southern Research to create a screening system to identify drugs that inhibit HIV replication.
The system can be used by pharmaceutical companies [...]
Quest for a cure - In Quest for a Cure, Peter Day reports on whether the US Food and Drug Administration will licence the HIV/AIDS drug Maraviroc.
Maraviroc, a new HIV/AIDS drug was developed by Pfizer - the world’s largest pharmaceutical company - at its vast research and development center located at Sandwich in Kent, on the southeastern tip of [...]
AIDS researchers find protein that greatly boosts HIV infection - German AIDS researchers have discovered a protein common in semen that boosts the infectious potential of HIV 100,000-fold - a remarkable finding that may show how the virus can spread through sexual contact and also suggests new strategies to stop the epidemic.
If scientists can find a drug or chemical that blocks these infection-promoting proteins, it [...]
Gossypol Biological Properties - Gossypol:
is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
is antimalarial being the selective inhibitor of Plasmodium falciparum (pfLDH over hLDHs), an essential enzyme for energy generation within malarial parasite.
posesses proapoptotic properties, probably due to the regulation of the Bax and Bcl2.
reversibly inhibits Calcineurin and binds to calmodulin.
inhibits replication [...]
FDA approves Merck’s Isentress for HIV - Oct 16, 2007 (Datamonitor via COMTEX) — MRK | charts | news | PowerRating — The FDA has granted Merck & Co.’s Isentress tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to [...]
Soya bean can help fight dreaded HIV, claims research - SOYA BEAN is packed with powerful punch. It not only has the power to absorb the heavy metals from the mother earth but also has the potential as a bio-fuel besides possessing the quality to fight the dreaded HIV.
Realising the potential Naithani Plant Genetics Laboratory of Botany Department, Allahabad University (AU), has approached the Council [...]
Immune cells fighting chronic infections become progressively ‘exhausted,’ ineffective - (PHILADELPHIA) – A new study of immune cells battling a chronic viral infection shows that the cells, called T cells, become exhausted by the fight in specific ways, undergoing profound changes that make them progressively less effective over time.
The findings also point to interventions that would reverse the changes, suggesting that novel therapies could be [...]
CLC bio joins $2.5M research project on HIV, bird flu, and other RNA-based diseases - Aarhus Denmark, April 30, 2007 — CLC bio, the IT University of Copenhagen, and the Department of Molecular Biology at the interdisciplinary nano science centre (iNANO) of University of Aarhus are proud to announce that the Danish Council for Strategic Research has approved to fund the ambitious and ground-breaking research project PC Mini Grids for [...]
Setting The Stage To Find Drugs Against SARS - Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002. Researchers from Brookhaven’s biology department and the National Synchrotron Light Source (NSLS) [...]
Protected: BIT’s 4th Annual Congress of International Drug Discovery Science & Technology 2006 (IDDST-2006) - There is no excerpt because this is a protected post.
Links
|
|
